Literature DB >> 22698731

The insulin-like growth factor mutation database (IGFmdb).

Harinda Rajapaksha1, Clair Alvino, Peter McCarthy, Briony E Forbes.   

Abstract

Insulin-like growth factors (IGF-I and IGF-II), and insulin are evolutionarily conserved hormonal regulators of eukaryotic growth and development. Through interactions with their cognate receptors, all three molecules can influence cellular growth, proliferation, differentiation, migration, and survival, as well as metabolic processes. As such, perturbations in signaling by IGFs and insulin are a well-documented cause of altered growth, development and survival during both embryonic and post-natal life. A key approach in understanding how IGFs and insulin elicit their biological effects has been through identifying structural features of the ligands that influence their receptor interactions. Over the years, the study of many hundreds of specifically engineered IGF and insulin analogues has provided a wealth of knowledge about how specific residues of these ligands contribute to ligand:receptor interactions. Some analogues have even provided the basis for designing therapeutic agents for the treatment of IGF and insulin-related diseases. As the list of IGF and insulin analogues continues to grow we find that, while many have been produced and studied, it would be of considerable value to have a central repository from which information about specific analogues and their receptor binding data were readily available in an easily searchable and comparable format. To address this, we have created the "Insulin-like growth factor mutation database" (IGFmdb). The IGFmdb is a web-based curated database of annotated ligand analogues and their receptor binding affinities that can be accessed via http://www.adelaide.edu.au/igfmutation. Currently the IGFmdb contains receptor-binding data for 67 IGF-II analogues that were publicly accessible prior to 2012, as well as 67 IGF-I analogues, including all of those produced and characterised in our laboratory. A small number of these are IGF species homologues. There are also 32 insulin analogues within IGFmdb that were reported within the included IGF analogue studies, representing only a small fraction of existing insulin mutants. Future developments of the IGFmdb will incorporate receptor-binding data for all publicly accessible IGF-I analogues and the data will be expanded to include IGF-binding protein (IGFBP) binding affinities. Crown
Copyright © 2012. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22698731     DOI: 10.1016/j.ghir.2012.05.001

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  5 in total

1.  Subventricular zone adult mouse neural stem cells require insulin receptor for self-renewal.

Authors:  Shravanthi Chidambaram; Fernando J Velloso; Deborah E Rothbard; Kaivalya Deshpande; Yvelande Cajuste; Kristin M Snyder; Eduardo Fajardo; Andras Fiser; Nikos Tapinos; Steven W Levison; Teresa L Wood
Journal:  Stem Cell Reports       Date:  2022-05-05       Impact factor: 7.294

2.  Overexpression of lncRNA IRAIN restrains the progression and Temozolomide resistance of glioma via repressing IGF-1R-PI3K-NF-κB signaling pathway.

Authors:  Aishun Guo; Guixia Fang; Zhenrong Lin; Shuishun Zheng; Zhijun Zhuang; Ruisheng Lin; Yanling Lin
Journal:  Histol Histopathol       Date:  2022-02-01       Impact factor: 2.130

3.  Anabolic effects of IGF-1 signaling on the skeleton.

Authors:  Candice G T Tahimic; Yongmei Wang; Daniel D Bikle
Journal:  Front Endocrinol (Lausanne)       Date:  2013-02-04       Impact factor: 5.555

4.  Enhanced Production of Insulin-like Growth Factor I Protein in Escherichia coli by Optimization of Five Key Factors.

Authors:  Javad Ranjbari; Valiollah Babaeipour; Hossein Vahidi; Hamidreza Moghimi; Mohammad Reza Mofid; Mohammad Mehdi Namvaran; Sevda Jafari
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

5.  Recombinant production of mecasermin in E. coli expression system.

Authors:  S Jafari; V Babaeipour; H A Eslampanah Seyedi; M Rahaie; M R Mofid; L Haddad; M M Namvaran; J Fallah
Journal:  Res Pharm Sci       Date:  2014 Nov-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.